Investing.com -- Solventum Corp (NYSE:SOLV) reported second quarter results that exceeded analyst expectations and raised its full-year guidance, driven by strong organic sales growth across all business segments. The organic sales growth reflected strong performance across all segments, primarily driven by volume and product mix, including the benefit of advance orders placed ahead of ERP cutovers. The company's MedSurg segment led revenue growth with sales of $1.4 billion, up 12.7% on a reported basis and 8.9% organically. Dental Solutions grew 17.0% on a reported basis and 15.2% organically, while Infection Prevention and Surgical Solutions increased 11.3% on a reported basis and 10.1% organically. Related articlesSolventum beats estimates, raises guidance on strong growthThese 2 stocks are best positioned to benefit from higher uranium prices: analystThis sector is 'poised for a big, beautiful year': Truist